Physician profile
Robert C Pennington
NPI 1144224080
$1,890.94
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $557 · 2020: $795 · 2021: $520 · 2022: $18.41.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $323.33 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $174.80 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $155.72 | 2019-2021 | |
| Amgen INC. | $143.55 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.51 | 2019-2021 | |
| Pfizer INC. | $117.03 | 2019-2021 | |
| Amarin Pharma, INC. | $111.63 | 2019-2021 | |
| Abbvie INC. | $83.56 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $72.22 | 2019-2021 | |
| Lilly USA, LLC | $67.93 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.72 | 2019-2021 | |
| Glaxosmithkline, LLC. | $59.47 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $52.63 | 2019-2021 | |
| Ibsa Pharma INC. | $52.38 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $49.54 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $48.96 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $37.49 | 2019-2021 | |
| Neos Therapeutics, LP | $26.23 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $25.60 | 2019-2021 | |
| Eisai INC. | $15.73 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $15.05 | 2020 | |
| Adlon Therapeutics L.P. | $14.30 | 2020 | |
| Esperion Therapeutics, INC. | $13.89 | 2020 | |
| Allergan, INC. | $12.85 | 2020 | |
| Genentech USA, INC. | $11.67 | 2020 | |
| Gilead Sciences, INC. | $11.15 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Pennington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.